Cargando…

Evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial M5717 using segmented mixed effect models

BACKGROUND: Evaluation of parasite clearance patterns in experimental human infection trials helps increase understanding of drug action. In a previously reported phase Ib trial of a new investigational anti-malarial drug M5717, parasite clearance showed a biphasic linear pattern: slow removal phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Xiaoyan, Li, Ying, Bagchus, Wilhelmina, Yalkinoglu, Özkan, Bezuidenhout, Deon, Tappert, Aliona, McCarthy, James, Marquart, Louise, Oeuvray, Claude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303793/
https://www.ncbi.nlm.nih.gov/pubmed/37381013
http://dx.doi.org/10.1186/s12936-023-04627-x
_version_ 1785065359148056576
author Yin, Xiaoyan
Li, Ying
Bagchus, Wilhelmina
Yalkinoglu, Özkan
Bezuidenhout, Deon
Tappert, Aliona
McCarthy, James
Marquart, Louise
Oeuvray, Claude
author_facet Yin, Xiaoyan
Li, Ying
Bagchus, Wilhelmina
Yalkinoglu, Özkan
Bezuidenhout, Deon
Tappert, Aliona
McCarthy, James
Marquart, Louise
Oeuvray, Claude
author_sort Yin, Xiaoyan
collection PubMed
description BACKGROUND: Evaluation of parasite clearance patterns in experimental human infection trials helps increase understanding of drug action. In a previously reported phase Ib trial of a new investigational anti-malarial drug M5717, parasite clearance showed a biphasic linear pattern: slow removal phase with a near flat clearance rate followed by a fast clearance phase with a steep slope. In this study three statistical approaches were implemented and compared to estimate the parasite clearance rate for each phase and the time point corresponding to the change of clearance rates (changepoint between the two phases). METHODS: Data using three M5717 doses 150 mg (n = 6), 400 mg (n = 8), 800 mg (n = 8) were used to estimate biphasic clearance rates. Three models were investigated: firstly, segmented mixed models with estimated changepoint—models with/without random effects in various parameters were compared. Secondly, a segmented mixed model using grid search—this method is similar to the first except that changepoints were not estimated, instead they were selected based on model fit from given candidate values. Thirdly, a two-stage approach whereby a segmented regression model fit to each participant followed by a meta-analysis method. Hourly rate of parasite clearance (HRPC) interpreted as the percentage of parasites removed each hour was calculated. RESULTS: The three models generated similar results. Using segmented mixed models, the estimated changepoints after treatment in hours (95% CI) were: 150 mg: 33.9 (28.7, 39.1); 400 mg: 57.4 (52.5, 62.4); and 800 mg: 52.8 (47.4, 58.1). For all three treatment groups, there was nearly no clearance before the changepoints, but rapid clearance in the second phase (HRPC [95% CI]): 150 mg: 16.8% (14.3, 19.1%); 400 mg: 18.6% (16.0, 21.1%); and 800 mg: 11.7% (9.3, 14.1%). CONCLUSIONS: All three statistical approaches are effective tools to characterize the bi-phasic clearance of M5717 in the phase 1b experimental Plasmodium falciparum malaria human infection study. The statistical approaches produced similar results to estimate the two-phase clearance rates and the changepoint for each treatment dose of M5717. However, the segmented mixed model with random changepoints has several advantages: it is computationally efficient, provides precision for changepoint estimates and is robust concerning outlying datapoints or individuals. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12936-023-04627-x.
format Online
Article
Text
id pubmed-10303793
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103037932023-06-29 Evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial M5717 using segmented mixed effect models Yin, Xiaoyan Li, Ying Bagchus, Wilhelmina Yalkinoglu, Özkan Bezuidenhout, Deon Tappert, Aliona McCarthy, James Marquart, Louise Oeuvray, Claude Malar J Research BACKGROUND: Evaluation of parasite clearance patterns in experimental human infection trials helps increase understanding of drug action. In a previously reported phase Ib trial of a new investigational anti-malarial drug M5717, parasite clearance showed a biphasic linear pattern: slow removal phase with a near flat clearance rate followed by a fast clearance phase with a steep slope. In this study three statistical approaches were implemented and compared to estimate the parasite clearance rate for each phase and the time point corresponding to the change of clearance rates (changepoint between the two phases). METHODS: Data using three M5717 doses 150 mg (n = 6), 400 mg (n = 8), 800 mg (n = 8) were used to estimate biphasic clearance rates. Three models were investigated: firstly, segmented mixed models with estimated changepoint—models with/without random effects in various parameters were compared. Secondly, a segmented mixed model using grid search—this method is similar to the first except that changepoints were not estimated, instead they were selected based on model fit from given candidate values. Thirdly, a two-stage approach whereby a segmented regression model fit to each participant followed by a meta-analysis method. Hourly rate of parasite clearance (HRPC) interpreted as the percentage of parasites removed each hour was calculated. RESULTS: The three models generated similar results. Using segmented mixed models, the estimated changepoints after treatment in hours (95% CI) were: 150 mg: 33.9 (28.7, 39.1); 400 mg: 57.4 (52.5, 62.4); and 800 mg: 52.8 (47.4, 58.1). For all three treatment groups, there was nearly no clearance before the changepoints, but rapid clearance in the second phase (HRPC [95% CI]): 150 mg: 16.8% (14.3, 19.1%); 400 mg: 18.6% (16.0, 21.1%); and 800 mg: 11.7% (9.3, 14.1%). CONCLUSIONS: All three statistical approaches are effective tools to characterize the bi-phasic clearance of M5717 in the phase 1b experimental Plasmodium falciparum malaria human infection study. The statistical approaches produced similar results to estimate the two-phase clearance rates and the changepoint for each treatment dose of M5717. However, the segmented mixed model with random changepoints has several advantages: it is computationally efficient, provides precision for changepoint estimates and is robust concerning outlying datapoints or individuals. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12936-023-04627-x. BioMed Central 2023-06-28 /pmc/articles/PMC10303793/ /pubmed/37381013 http://dx.doi.org/10.1186/s12936-023-04627-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yin, Xiaoyan
Li, Ying
Bagchus, Wilhelmina
Yalkinoglu, Özkan
Bezuidenhout, Deon
Tappert, Aliona
McCarthy, James
Marquart, Louise
Oeuvray, Claude
Evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial M5717 using segmented mixed effect models
title Evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial M5717 using segmented mixed effect models
title_full Evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial M5717 using segmented mixed effect models
title_fullStr Evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial M5717 using segmented mixed effect models
title_full_unstemmed Evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial M5717 using segmented mixed effect models
title_short Evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial M5717 using segmented mixed effect models
title_sort evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial m5717 using segmented mixed effect models
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303793/
https://www.ncbi.nlm.nih.gov/pubmed/37381013
http://dx.doi.org/10.1186/s12936-023-04627-x
work_keys_str_mv AT yinxiaoyan evaluationofamultiphasicparasiteclearanceprofileaftertreatmentofexperimentalhumaninfectionwiththeinvestigationalantimalarialm5717usingsegmentedmixedeffectmodels
AT liying evaluationofamultiphasicparasiteclearanceprofileaftertreatmentofexperimentalhumaninfectionwiththeinvestigationalantimalarialm5717usingsegmentedmixedeffectmodels
AT bagchuswilhelmina evaluationofamultiphasicparasiteclearanceprofileaftertreatmentofexperimentalhumaninfectionwiththeinvestigationalantimalarialm5717usingsegmentedmixedeffectmodels
AT yalkinogluozkan evaluationofamultiphasicparasiteclearanceprofileaftertreatmentofexperimentalhumaninfectionwiththeinvestigationalantimalarialm5717usingsegmentedmixedeffectmodels
AT bezuidenhoutdeon evaluationofamultiphasicparasiteclearanceprofileaftertreatmentofexperimentalhumaninfectionwiththeinvestigationalantimalarialm5717usingsegmentedmixedeffectmodels
AT tappertaliona evaluationofamultiphasicparasiteclearanceprofileaftertreatmentofexperimentalhumaninfectionwiththeinvestigationalantimalarialm5717usingsegmentedmixedeffectmodels
AT mccarthyjames evaluationofamultiphasicparasiteclearanceprofileaftertreatmentofexperimentalhumaninfectionwiththeinvestigationalantimalarialm5717usingsegmentedmixedeffectmodels
AT marquartlouise evaluationofamultiphasicparasiteclearanceprofileaftertreatmentofexperimentalhumaninfectionwiththeinvestigationalantimalarialm5717usingsegmentedmixedeffectmodels
AT oeuvrayclaude evaluationofamultiphasicparasiteclearanceprofileaftertreatmentofexperimentalhumaninfectionwiththeinvestigationalantimalarialm5717usingsegmentedmixedeffectmodels